Market Leadership & Scale: Jinxin is a leading global provider of assisted reproductive technology (ART) services, with a significant market share in key regions, particularly in China and through its HRC Fertility operations in the United States, providing a strong platform for scale and brand recognition.

High Success Rates & Medical Expertise: The company boasts high success rates in its ART procedures, underpinned by a highly experienced medical team and continuous investment in advanced medical techniques and protocols, which is a critical differentiator in attracting patients.

Comprehensive Service Portfolio: NAMI offers a broad spectrum of reproductive health services, including IVF, IUI, genetic testing, egg/sperm freezing, and other related services, providing a one-stop solution for patients and capturing a wider range of demand.